Pituitary Imaging Abnormalities and Related Endocrine Disorders in Erdheim–Chester Disease
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Overview and Objectives
2.2. Procedures
2.3. Statistical Analysis
3. Results
3.1. Types of Abnormal Pituitary Imaging
3.2. Types of Pituitary Endocrinopathies
3.3. Factors Associated with Abnormal Pituitary Imaging in Subjects with ECD
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chester, W. Über Lipoidgranulomatose. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 1930, 279, 561–602. [Google Scholar] [CrossRef]
- Campo, E.; Swerdlow, S.H.; Harris, N.L.; Pileri, S.; Stein, H.; Jaffe, E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011, 117, 5019–5032. [Google Scholar] [CrossRef] [Green Version]
- Cavalli, G.; Guglielmi, B.; Berti, A.; Campochiaro, C.; Sabbadini, M.G.; Dagna, L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: Comprehensive review of the literature and of 10 new cases. Ann. Rheum. Dis. 2013, 72, 1691–1695. [Google Scholar] [CrossRef]
- Chakraborty, R.; Hampton, O.A.; Shen, X.; Simko, S.J.; Shih, A.; Abhyankar, H.; Lim, K.P.; Covington, K.R.; Trevino, L.; Dewal, N.; et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014, 124, 3007–3015. [Google Scholar] [CrossRef]
- Diamond, E.L.; Durham, B.H.; Haroche, J.; Yao, Z.; Ma, J.; Parikh, S.A.; Wang, Z.; Choi, J.; Kim, E.; Cohen-Aubart, F.; et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2016, 6, 154–165. [Google Scholar] [CrossRef] [Green Version]
- Haroche, J.; Charlotte, F.; Arnaud, L.; von Deimling, A.; Helias-Rodzewicz, Z.; Hervier, B.; Cohen-Aubart, F.; Launay, D.; Lesot, A.; Mokhtari, K.; et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012, 120, 2700–2703. [Google Scholar] [CrossRef] [Green Version]
- Nelson, D.S.; van Halteren, A.; Quispel, W.T.; van den Bos, C.; Bovee, J.V.; Patel, B.; Badalian-Very, G.; van Hummelen, P.; Ducar, M.; Lin, L.; et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015, 54, 361–368. [Google Scholar] [CrossRef]
- Brown, N.A.; Furtado, L.V.; Betz, B.L.; Kiel, M.J.; Weigelin, H.C.; Lim, M.S.; Elenitoba-Johnson, K.S. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 2014, 124, 1655–1658. [Google Scholar] [CrossRef] [Green Version]
- Shekhar, S.; Sinaii, N.; Irizarry-Caro, J.A.; Gahl, W.A.; Estrada-Veras, J.I.; Dave, R.; Papadakis, G.Z.; Tirosh, A.; Abel, B.S.; Klubo-Gwiezdzinska, J.; et al. Prevalence of Hypothyroidism in Patients with Erdheim-Chester Disease. JAMA Netw. Open 2020, 3, e2019169. [Google Scholar] [CrossRef]
- Shekhar, S.; Hannah-Shmouni, F.; Gahl, W.; Estrada-Veras, J.; Brien, K. MON-605 Hypothyroidism in Erdheim-Chester Disease: Experience from a Tertiary Care National Referral Center. J. Endocr. Soc. 2019, 3 (Suppl. 1). [Google Scholar] [CrossRef]
- Hannah-Shmouni, F.; Boyd, L.; Papadakis, G.Z.; Tirosh, A.; Gahl, W.A.; Estrada-Veras, J.I.; O’Brien, K. Association of BRAF V600E with Hypothalamic-Pituitary-Adrenal Axis Involvement in Erdheim-Chester Disease. Endocr. Metab. Sci. 2020, 1, 100051. [Google Scholar] [CrossRef]
- Estrada-Veras, J.I.; O’Brien, K.J.; Boyd, L.C.; Dave, R.H.; Durham, B.; Xi, L.; Malayeri, A.A.; Chen, M.Y.; Gardner, P.J.; Alvarado-Enriquez, J.R.; et al. The clinical spectrum of Erdheim-Chester disease: An observational cohort study. Blood Adv. 2017, 1, 357–366. [Google Scholar] [CrossRef] [Green Version]
- Papadakis, G.; Shekhar, S.; Irizarry-Caro, J.; Giannakakis, G.; Karantanas, A.; Gahl, W.; Brien, K.; Estrada-Veras, J.; Hannah-Shmouni, F. Increased metabolic activity of the adrenal glands assessed by 18F-FDG PET/CT in patients with Erdheim-Chester disease associated with the BRAF V600E disease causing variant. J. Nucl. Med. 2021, 62, 1112. [Google Scholar]
- Arnaud, L.; Gorochov, G.; Charlotte, F.; Lvovschi, V.; Parizot, C.; Larsen, M.; Ghillani-Dalbin, P.; Hervier, B.; Kahn, J.E.; Deback, C.; et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients. Blood 2011, 117, 2783–2790. [Google Scholar] [CrossRef] [Green Version]
- Haroutunian, S.G.; O’Brien, K.J.; Estrada-Veras, J.I.; Yao, J.; Boyd, L.C.; Mathur, K.; Gahl, W.A.; Mirmomen, S.M.; Malayeri, A.A.; Kleiner, D.E.; et al. Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim(-)Chester Disease. J. Clin. Med. 2018, 7, 243. [Google Scholar] [CrossRef] [Green Version]
- Nikpanah, M.; Kim, L.; Mirmomen, S.M.; Symons, R.; Papageorgiou, I.; Gahl, W.A.; O’Brien, K.; Estrada-Veras, J.I.; Malayeri, A.A. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF(V600E) mutation. Eur. Radiol. 2018, 28, 3751–3759. [Google Scholar] [CrossRef]
- Courtillot, C.; Laugier Robiolle, S.; Cohen Aubart, F.; Leban, M.; Renard-Penna, R.; Drier, A.; Charlotte, F.; Amoura, Z.; Touraine, P.; Haroche, J. Endocrine Manifestations in a Monocentric Cohort of 64 Patients With Erdheim-Chester Disease. J. Clin. Endocrinol. Metab. 2016, 101, 305–313. [Google Scholar] [CrossRef]
- Arnaud, L.; Hervier, B.; Neel, A.; Hamidou, M.A.; Kahn, J.E.; Wechsler, B.; Perez-Pastor, G.; Blomberg, B.; Fuzibet, J.G.; Dubourguet, F.; et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: A multicenter survival analysis of 53 patients. Blood 2011, 117, 2778–2782. [Google Scholar] [CrossRef]
- Haroche, J.; Cohen-Aubart, F.; Emile, J.F.; Arnaud, L.; Maksud, P.; Charlotte, F.; Cluzel, P.; Drier, A.; Hervier, B.; Benameur, N.; et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013, 121, 1495–1500. [Google Scholar] [CrossRef] [Green Version]
- Diamond, E.L.; Durham, B.H.; Ulaner, G.A.; Drill, E.; Buthorn, J.; Ki, M.; Bitner, L.; Cho, H.; Young, R.J.; Francis, J.H.; et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019, 567, 521–524. [Google Scholar] [CrossRef]
- Goyal, G.; Heaney, M.L.; Collin, M.; Cohen Aubart, F.; Vaglio, A.; Durham, B.H.; Hershkovitz-Rokah, O.; Girschikofsky, M.; Jacobsen, E.D.; Toyama, K.; et al. Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood 2020, 135, 1929–1945. [Google Scholar] [CrossRef]
- Tien, R.D.; Newton, T.H.; McDermott, M.W.; Dillon, W.P.; Kucharczyk, J. Thickened pituitary stalk on MR images in patients with diabetes insipidus and Langerhans cell histiocytosis. AJNR Am. J. Neuroradiol. 1990, 11, 703–708. [Google Scholar]
- Chaudhary, V.; Bano, S. Imaging of the pituitary: Recent advances. Indian J. Endocrinol. Metab. 2011, 15 (Suppl. 3), S216–S223. [Google Scholar] [CrossRef]
- Fleseriu, M.; Hashim, I.A.; Karavitaki, N.; Melmed, S.; Murad, M.H.; Salvatori, R.; Samuels, M.H. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2016, 101, 3888–3921. [Google Scholar] [CrossRef]
- Gupta, V.; Lee, M. Central hypothyroidism. Indian J. Endocrinol. Metab. 2011, 15 (Suppl. 2), S99–S106. [Google Scholar] [CrossRef]
- Boyd, L.C.; O’Brien, K.J.; Ozkaya, N.; Lehky, T.; Meoded, A.; Gochuico, B.R.; Hannah-Shmouni, F.; Nath, A.; Toro, C.; Gahl, W.A.; et al. Neurological manifestations of Erdheim-Chester Disease. Ann. Clin. Transl. Neurol. 2020, 7, 497–506. [Google Scholar] [CrossRef]
- Bergsneider, M.; Mirsadraei, L.; Yong, W.H.; Salamon, N.; Linetsky, M.; Wang, M.B.; McArthur, D.L.; Heaney, A.P. The pituitary stalk effect: Is it a passing phenomenon? J. Neurooncol. 2014, 117, 477–484. [Google Scholar] [CrossRef]
- Murai, I.; Garris, P.A.; Ben-Jonathan, N. Time-dependent increase in plasma prolactin after pituitary stalk section: Role of posterior pituitary dopamine. Endocrinology 1989, 124, 2343–2349. [Google Scholar] [CrossRef]
- Orija, I.B.; Weil, R.J.; Hamrahian, A.H. Pituitary incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26, 47–68. [Google Scholar] [CrossRef]
- Hall, W.A.; Luciano, M.G.; Doppman, J.L.; Patronas, N.J.; Oldfield, E.H. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann. Intern. Med. 1994, 120, 817–820. [Google Scholar] [CrossRef]
- Kuo, M.; Maya, M.M.; Bonert, V.; Melmed, S. Prospective Evaluation of Incidental Pituitary Imaging Findings in the Sella Turcica. J. Endocr. Soc. 2021, 5, bvaa186. [Google Scholar] [CrossRef]
- Famini, P.; Maya, M.M.; Melmed, S. Pituitary magnetic resonance imaging for sellar and parasellar masses: Ten-year experience in 2598 patients. J. Clin. Endocrinol. Metab. 2011, 96, 1633–1641. [Google Scholar] [CrossRef]
- Kumar, P.; Singh, A.; Gamanagatti, S.; Kumar, S.; Chandrashekhara, S.H. Imaging findings in Erdheim-Chester disease: What every radiologist needs to know. Pol. J. Radiol. 2018, 83, e54–e62. [Google Scholar] [CrossRef] [PubMed]
- Veyssier-Belot, C.; Cacoub, P.; Caparros-Lefebvre, D.; Wechsler, J.; Brun, B.; Remy, M.; Wallaert, B.; Petit, H.; Grimaldi, A.; Wechsler, B.; et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine 1996, 75, 157–169. [Google Scholar] [CrossRef]
- Drier, A.; Haroche, J.; Savatovsky, J.; Godenèche, G.; Dormont, D.; Chiras, J.; Amoura, Z.; Bonneville, F. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 2010, 255, 586–594. [Google Scholar] [CrossRef] [PubMed]
- Sedrak, P.; Ketonen, L.; Hou, P.; Guha-Thakurta, N.; Williams, M.D.; Kurzrock, R.; Debnam, J.M. Erdheim-Chester Disease of the Central Nervous System: New Manifestations of a Rare Disease. Am. J. Neuroradiol. 2011, 32, 2126. [Google Scholar] [CrossRef] [Green Version]
- Lachenal, F.; Cotton, F.; Desmurs-Clavel, H.; Haroche, J.; Taillia, H.; Magy, N.; Hamidou, M.; Salvatierra, J.; Piette, J.-C.; Vital-Durand, D.; et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: Report of 6 cases and systematic review of the literature. J. Neurol. 2006, 253, 1267–1277. [Google Scholar] [CrossRef] [PubMed]
- Shekhar, S.; Irizarry-Caro, J.A.; Hannah-Shmouni, F. Unpublished Work. 2021.
- Gubbi, S.; Hannah-Shmouni, F.; Verbalis, J.G.; Koch, C.A. Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract. Res. Clin. Endocrinol. Metab. 2019, 33, 101371. [Google Scholar] [CrossRef]
- Shekhar, S.; Irizarry-Caro, J.A.; Sinaii, N.; Gahl, W.; Estrada-Veras, J.I.; Dave, R.; Papadakis, G.Z.; Patronas, N.; Stratakis, C.A.; O’Brien, K.; et al. Abnormal Pituitary Imaging and Associated Endocrine Dysfunctions in Erdheim-Chester Disease. J. Endocr. Soc. 2021, 5 (Suppl. 1), A622. [Google Scholar] [CrossRef]
Variable | Study Cohort (ECD) (n = 61) | Abnormal Pituitary Imaging (n = 29) | Normal Pituitary Imaging (n = 32) | p Value |
---|---|---|---|---|
Age, mean (SD), years | 54.3 (10.9) | 50.6 (11.7) | 57.7 (9.0) | 0.010 |
Sex, Female No. (%) | 15 (24.6) | 7 (46.7%) | 8 (53.3%) | 1.0 |
BMI, median (IQR) | 27.8 (24.8–32.9) | 27.8 (24.7–33.3) | 28.4 (25.3–32.7) | 0.69 |
BRAFpathogenic variant, positive No. (%)/n | 31 (54.4)/57 | 16 (51.6%) | 15 (48.4%) | 0.60 |
Panhypopituitarism No. (%) | 9 (14.8%) | 9 (100.0%) | 0 | <0.001 |
Diabetes insipidus No. (%) | 22 (36.1%) | 18 (81.8%) | 4 (18.2%) | <0.001 |
Central Hypogonadism | 29 (47.54%) | 19 (65.52%) | 13 (40.63%) | 0.073 |
Central Adrenal Insufficiency | 13 (21.3%) | 6 (24.14%) | 6 (18.75%) | 0.76 |
Central Hypothyroidism | 6 (9.84%) | 5 (17.24%) | 1 (3.13%) | 0.09 |
hsCRP, median (IQR)/n, mg/L | 12.2 (3.1–45.4) | 13.3 (3.3–54.3) | 6.9 (3.1–45.4) | 0.82 |
ESR, median (IQR)/n, mm/h | 23 (11.0–38.0) | 28 (12.0–49.0) | 21 (9.5–26.5) | 0.079 |
Number of deficits, median (IQR) | 1.0 (0–2.0) | 2.0 (1.0–3.0) | 1.0 (0–1.0) | 0.004 |
Imaging Abnormality | Number of Subjects |
---|---|
Thickened pituitary stalk | 15 (24.6%) |
Abnormal enhancement | 11 (18.0%) |
Suprasellar mass | 2 (3.3%) |
Loss of the posterior pituitary bright spot | 22 (36.1%) |
Small pituitary | 9 (14.8%) |
Stalk deviation | 7 (11.5%) |
Pituitary encasement | 3 (4.9%) |
Empty sella | |
Complete | 3 (4.9%) |
Partial | 4 (6.6%) |
Microadenoma | 1 (1.6%) |
Pars Intermedia cyst (incidental finding) | 3 (4.9%) |
Rathke’s cyst (incidental finding) | 1 (1.6%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shekhar, S.; Irizarry-Caro, J.A.; Sinaii, N.; Gahl, W.A.; Estrada-Veras, J.I.; Dave, R.H.; Gochuico, B.R.; Papadakis, G.Z.; Patronas, N.; Stratakis, C.A.; et al. Pituitary Imaging Abnormalities and Related Endocrine Disorders in Erdheim–Chester Disease. Cancers 2021, 13, 4126. https://doi.org/10.3390/cancers13164126
Shekhar S, Irizarry-Caro JA, Sinaii N, Gahl WA, Estrada-Veras JI, Dave RH, Gochuico BR, Papadakis GZ, Patronas N, Stratakis CA, et al. Pituitary Imaging Abnormalities and Related Endocrine Disorders in Erdheim–Chester Disease. Cancers. 2021; 13(16):4126. https://doi.org/10.3390/cancers13164126
Chicago/Turabian StyleShekhar, Skand, Jorge A. Irizarry-Caro, Ninet Sinaii, William A. Gahl, Juvianee I. Estrada-Veras, Rahul H. Dave, Bernadette R. Gochuico, Georgios Z. Papadakis, Nicholas Patronas, Constantine A. Stratakis, and et al. 2021. "Pituitary Imaging Abnormalities and Related Endocrine Disorders in Erdheim–Chester Disease" Cancers 13, no. 16: 4126. https://doi.org/10.3390/cancers13164126